Genfit SA's announcement April 24 that it will need more time to enroll the first 1,000 patients in a Phase III study for its non-alcoholic steatohepatitis (NASH) candidate elafibranor likely increases the edge Intercept Pharmaceuticals Inc. already had in reaching the market first with its own Phase III candidate, Ocaliva (obeticholic acid).
Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal
Firm cites heavy competition for NASH patients, as well as desire for balanced enrollment in elafibranor pivotal study. Competitor Intercept pushed back its Phase III enrollment timeline this past February.
More from Clinical Trials
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
More from R&D
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.